Comments
Loading...

Structure Therapeutics Analyst Ratings

GPCRNASDAQ
Logo brought to you by Benzinga Data
$24.43
0.612.58%
At close: -
$24.43
0.000.00%
After Hours: 4:00 PM EDT
Q1 2025 Earnings were released on Thu May 8th, after the market close
Consensus Rating1
Buy
Highest Price Target1
$118.00
Lowest Price Target1
$40.00
Consensus Price Target1
$74.85

Structure Therapeutics Analyst Ratings and Price Targets | NASDAQ:GPCR | Benzinga

Structure Therapeutics Inc has a consensus price target of $74.85 based on the ratings of 14 analysts. The high is $118 issued by Morgan Stanley on September 23, 2024. The low is $40 issued by BMO Capital on February 28, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Citigroup, and HC Wainwright & Co. on May 12, 2025, May 2, 2025, and April 22, 2025, respectively. With an average price target of $71.67 between HC Wainwright & Co., Citigroup, and HC Wainwright & Co., there's an implied 193.36% upside for Structure Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Dec 24
1
Jan
1
Feb
1
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Citigroup
Citizens Capital Markets
Stifel
JMP Securities

1calculated from analyst ratings

Analyst Ratings for Structure Therapeutics

Buy NowGet Alert
05/12/2025Buy Now207%HC Wainwright & Co.
Andrew Fein55%
$80 → $75MaintainsBuyGet Alert
05/02/2025Buy Now145.6%Citigroup
Samantha Semenkow33%
→ $60Initiates → BuyGet Alert
04/22/2025Buy Now227.47%HC Wainwright & Co.
Andrew Fein55%
$80 → $80MaintainsBuyGet Alert
02/28/2025Buy Now256.12%Citizens Capital Markets
Jonathan Wolleben69%
$91 → $87MaintainsMarket OutperformGet Alert
02/28/2025Buy NowWilliam Blair
Andy Hsieh26%
Initiates → OutperformGet Alert
01/08/2025Buy Now104.67%Stifel
Annabel Samimy66%
→ $50Initiates → BuyGet Alert
12/20/2024Buy Now227.47%HC Wainwright & Co.
Andrew Fein55%
$80 → $80ReiteratesBuy → BuyGet Alert
12/19/2024Buy Now227.47%HC Wainwright & Co.
Andrew Fein55%
$80 → $80ReiteratesBuy → BuyGet Alert
12/18/2024Buy Now272.49%JMP Securities
Jonathan Wolleben69%
$91 → $91ReiteratesMarket Outperform → Market OutperformGet Alert
12/04/2024Buy Now227.47%HC Wainwright & Co.
Andrew Fein55%
→ $80Initiates → BuyGet Alert
09/23/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
09/23/2024Buy Now383.01%Morgan Stanley
Terence Flynn65%
→ $118Initiates → OverweightGet Alert
09/16/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/19/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/15/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/09/2024Buy Now252.03%JMP Securities
Jonathan Wolleben69%
$91 → $86MaintainsMarket OutperformGet Alert
07/01/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
06/20/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
06/07/2024Buy Now309.33%BMO Capital
Evan David Seigerman45%
$83 → $100MaintainsOutperformGet Alert
06/03/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
05/21/2024Buy Now166.07%JP Morgan
Hardik Parikh10%
→ $65Initiates → OverweightGet Alert
05/10/2024Buy Now272.49%JMP Securities
Jonathan Wolleben69%
$91 → $91ReiteratesMarket Outperform → Market OutperformGet Alert
05/03/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
04/18/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
$65 → $65ReiteratesOverweight → OverweightGet Alert
04/09/2024Buy Now166.07%Cantor Fitzgerald
Prakhar Agrawal34%
→ $65Initiates → OverweightGet Alert
03/08/2024Buy Now272.49%JMP Securities
Jonathan Wolleben69%
$91 → $91ReiteratesMarket Outperform → Market OutperformGet Alert
11/20/2023Buy Now272.49%JMP Securities
Jonathan Wolleben69%
→ $91ReiteratesMarket Outperform → Market OutperformGet Alert
11/15/2023Buy Now272.49%JMP Securities
Jonathan Wolleben69%
$90 → $91MaintainsMarket OutperformGet Alert
10/27/2023Buy Now280.68%Piper Sandler
Yasmeen Rahimi55%
$58 → $93MaintainsOverweightGet Alert
10/26/2023Buy Now280.68%Piper Sandler
Yasmeen Rahimi55%
$58 → $93MaintainsOverweightGet Alert
10/19/2023Buy Now268.4%JMP Securities
Jonathan Wolleben69%
→ $90Initiates → Market OutperformGet Alert
10/03/2023Buy Now239.75%BMO Capital
Evan David Seigerman45%
$40 → $83MaintainsOutperformGet Alert
09/29/2023Buy Now223.37%Jefferies
Chris Howerton62%
$50 → $79MaintainsBuyGet Alert
07/27/2023Buy Now137.41%Piper Sandler
Yasmeen Rahimi55%
→ $58Initiates → OverweightGet Alert
02/28/2023Buy Now104.67%Guggenheim
Seamus Fernandez57%
→ $50Initiates → BuyGet Alert
02/28/2023Buy Now63.73%BMO Capital
Evan Seigerman60%
→ $40Initiates → OutperformGet Alert
02/28/2023Buy Now39.17%Jefferies
Chris Howerton62%
→ $34Initiates → BuyGet Alert

FAQ

Q

What is the target price for Structure Therapeutics (GPCR) stock?

A

The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by HC Wainwright & Co. on May 12, 2025. The analyst firm set a price target for $75.00 expecting GPCR to rise to within 12 months (a possible 207.00% upside). 23 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Structure Therapeutics (GPCR)?

A

The latest analyst rating for Structure Therapeutics (NASDAQ:GPCR) was provided by HC Wainwright & Co., and Structure Therapeutics maintained their buy rating.

Q

When was the last upgrade for Structure Therapeutics (GPCR)?

A

There is no last upgrade for Structure Therapeutics

Q

When was the last downgrade for Structure Therapeutics (GPCR)?

A

There is no last downgrade for Structure Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Structure Therapeutics (GPCR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Structure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Structure Therapeutics was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.

Q

Is the Analyst Rating Structure Therapeutics (GPCR) correct?

A

While ratings are subjective and will change, the latest Structure Therapeutics (GPCR) rating was a maintained with a price target of $80.00 to $75.00. The current price Structure Therapeutics (GPCR) is trading at is $24.43, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch